Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal (GE) junction~  * No T1-2, N0, M0 disease~ * No palpable or biopsy-proven involvement of supraclavicular nodes or radiographically involved supraclavicular nodes (\> 1.5 cm in greatest dimension) for lesions in mid-thoracic, distal thoracic, or GE junction~    + Supraclavicular node involvement allowed provided there are upper thoracic esophagus primary lesions~ * Patients with involvement of celiac nodes (stations 15-20) are eligible if the primary lesion is mid-thoracic, distal esophagus, or GE junction~ * No evidence of distant metastases~* Tumor must be considered surgically resectable~  - Patients with T4, N0 tumors that are potentially resectable are eligible~* No clinically relevant pleural or peritoneal effusion that is not amenable to drainage~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥1,500/mm\^3~* Platelet count ≥100,000/mm\^3~* Hemoglobin ≥10 g/dL~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine clearance ≥ 45 mL/min~* No New York Heart Association class III or IV congestive heart failure~* Pregnant or nursing women are ineligible~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled infection~* No other severe underlying disease that would preclude study entry~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ~* No prior sensitivity or allergic reaction to pemetrexed disodium or carboplatin~* Able to swallow pills~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy for esophageal cancer~* No prior radiotherapy field that overlapped the anticipated fields of study radiotherapy~* No prior radiotherapy to \> 30% of the marrow cavity~* Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) must be able to discontinue use 2 days prior, during, and 2 days after pemetrexed disodium administration (5 days prior for long-life NSAIDs)~* Patients must not have been receiving cyclooxygenase-2 inhibitors at study entry and while receiving protocol therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Carboplatin (Type: EXPERIMENTAL): Pemetrexed+Carboplatin+Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).